Transgene’s Moment Of Truth Approaches

French biotech Transgene SA has been through a few transformations in its 37-year history, and the past couple of years have been particularly rocky. However, chairman and CEO Philippe Archinard sees light at the end of the tunnel as the new era of combination immunotherapy arrives.

“We have a few scars. It has not been very fun for us these past two years.” Dr. Philippe Archinard, chairman and CEO of Transgene SA, does not deny the company has had its troubles. However, in an interview with Scrip, he outlined why he believes French biotech company’s time may finally be coming.

Transgene’s valuation has been on a fairly steady downward trajectory for a long time. The pace accelerated in early 2014...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

26 Jun 2025

• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.